Ergomed plc announced its intention to appoint Dr. Jim Esinhart as a Non-Executive Director of the Company. Dr Esinhart’s appointment will become effective upon completion of due diligence by the Company’s Nominated Adviser.
 
Dr. Esinhart is widely recognized as a leading figure in the global contract research and pharmaceutical industry. He began his career in the industry at GlaxoSmithKline specializing in infectious disease research. He went on to co-found PharmaResearch Corporation in 1995 and in 2006 he joined Chiltern International and became CEO in 2012. From 2006 to 2017 company growth was more than 11x, with revenue growing to over $550 million and the global workforce to over 4,500. His successful tenure culminated in the sale of Chiltern to Covance in late 2017 for $1.2 billion.
 
Dr. Miroslav Reljanović, Executive Chairman of Ergomed, commented: “Jim is recognized as a true pioneer of the global CRO industry. Working with our new CFO, Richard Barfield, he built Chiltern into a leading mid-market global CRO and delivered significant shareholder value through its acquisition by Covance. Jim’s insight, experience and support will be invaluable as we deliver on Ergomed’s growth strategy across all of our business segments.”
 
Dr Jim Esinhart said: “I am delighted to have this opportunity to work with Ergomed’s management team and Board. Today, Ergomed is recognized across the biopharma industry as a high-value service provider with repeat and new customer demand driving expansion and growth. With a global footprint and acknowledged quality of services, Ergomed is well-positioned as a leading mid-tier global CRO focused on high-growth areas such as oncology, orphan drugs and pharmacovigilance. With the benefit of my experience, there are considerable opportunities ahead for Ergomed to continue building to address the growing needs in our industry, and the unmet needs of patients worldwide.”